Willow Biosciences Inc. Logo

Willow Biosciences Inc.

WLLW.TO

(1.0)
Stock Price

0,10 CAD

-178.41% ROA

-144.52% ROE

-0.82x PER

Market Cap.

11.803.027,00 CAD

28.88% DER

0% Yield

-956.12% NPM

Willow Biosciences Inc. Stock Analysis

Willow Biosciences Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Willow Biosciences Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (24%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (1.13x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 ROE

Negative ROE (-118.61%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-151.63%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Willow Biosciences Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Willow Biosciences Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Willow Biosciences Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Willow Biosciences Inc. Revenue
Year Revenue Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2019 4.584 100%
2020 10.000 54.16%
2021 133.000 92.48%
2022 821.000 83.8%
2023 2.696.000 69.55%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Willow Biosciences Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2019 2.671.560 100%
2020 7.257.000 63.19%
2021 11.511.000 36.96%
2022 7.473.000 -54.03%
2023 6.388.000 -16.98%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Willow Biosciences Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1.007.430 100%
2009 2.002.800 49.7%
2010 887.932 -125.56%
2011 928.262 4.34%
2012 625.291 -48.45%
2013 1.038.251 39.77%
2014 925.685 -12.16%
2015 721.124 -28.37%
2016 873.735 17.47%
2017 628.860 -38.94%
2019 8.241.601 92.37%
2020 6.417.000 -28.43%
2021 7.787.000 17.59%
2022 8.294.000 6.11%
2023 3.032.000 -173.55%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Willow Biosciences Inc. EBITDA
Year EBITDA Growth
1998 -202.122
1999 -114.435 -76.63%
2000 -179.967 36.41%
2001 -165.865 -8.5%
2002 -70.102 -136.61%
2003 13.118 634.4%
2004 -193.659 106.77%
2005 -442.643 56.25%
2006 -420.825 -5.18%
2007 -2.071.705 79.69%
2008 -1.110.623 -86.54%
2009 -1.983.518 44.01%
2010 -969.716 -104.55%
2011 -926.368 -4.68%
2012 -625.248 -48.16%
2013 -962.888 35.07%
2014 -865.255 -11.28%
2015 -111.630 -675.11%
2016 -842.846 86.76%
2017 -622.249 -35.45%
2019 -10.795.681 94.24%
2020 -13.509.000 20.09%
2021 -19.568.000 30.96%
2022 -15.454.000 -26.62%
2023 -6.744.000 -129.15%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Willow Biosciences Inc. Gross Profit
Year Gross Profit Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2019 4.584 100%
2020 10.000 54.16%
2021 133.000 92.48%
2022 821.000 83.8%
2023 2.696.000 69.55%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Willow Biosciences Inc. Net Profit
Year Net Profit Growth
1998 -202.122
1999 -114.435 -76.63%
2000 -183.156 37.52%
2001 -163.307 -12.15%
2002 -70.205 -132.61%
2003 -306.125 77.07%
2004 -217.793 -40.56%
2005 -390.352 44.21%
2006 -404.409 3.48%
2007 -1.652.348 75.53%
2008 -1.152.053 -43.43%
2009 -3.057.264 62.32%
2010 -3.216.858 4.96%
2011 -1.417.113 -127%
2012 -1.800.552 21.3%
2013 -1.387.172 -29.8%
2014 -865.372 -60.3%
2015 -1.310.540 33.97%
2016 -2.329.740 43.75%
2017 -1.857.192 -25.44%
2019 -44.566.590 95.83%
2020 -33.986.000 -31.13%
2021 -6.167.000 -451.09%
2022 -14.814.000 58.37%
2023 -8.924.000 -66%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Willow Biosciences Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 -18
1999 -97 82.29%
2000 -156 38.46%
2001 -139 -12.23%
2002 -60 -135.59%
2003 -300 80.33%
2004 -126 -138.1%
2005 -158 20.25%
2006 -118 -33.9%
2007 -348 65.99%
2008 -178 -96.05%
2009 -311 42.9%
2010 -268 -16.1%
2011 -107 -151.89%
2012 -129 17.19%
2013 -31 -312.9%
2014 -11 -210%
2015 -10 -11.11%
2016 -8 -12.5%
2017 -3 -300%
2019 -1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Willow Biosciences Inc. Free Cashflow
Year Free Cashflow Growth
1998 -114.000
1999 -114.435 0.38%
2000 -105.172 -8.81%
2001 281 37527.76%
2002 -375 174.93%
2003 -34 -1002.94%
2004 -150.113 99.98%
2005 -50.836 -195.29%
2006 -211.791 76%
2007 -2.408.378 91.21%
2008 -1.633.896 -47.4%
2009 -1.490.458 -9.62%
2010 -1.451.161 -2.71%
2011 -714.077 -103.22%
2012 -233.942 -205.24%
2013 -1.085.974 78.46%
2014 -676.768 -60.46%
2015 -651.152 -3.93%
2016 -1.519.832 57.16%
2017 -511.743 -196.99%
2019 -15.873.818 96.78%
2020 -13.777.000 -15.22%
2021 -19.993.000 31.09%
2022 -14.544.000 -37.47%
2023 -2.381.000 -510.84%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Willow Biosciences Inc. Operating Cashflow
Year Operating Cashflow Growth
1998 -114.000
1999 -114.435 0.38%
2000 -105.172 -8.81%
2001 281 37527.76%
2002 -375 174.93%
2003 -34 -1002.94%
2004 -150.113 99.98%
2005 -50.836 -195.29%
2006 -211.791 76%
2007 -1.105.101 80.84%
2008 -922.612 -19.78%
2009 -889.158 -3.76%
2010 -865.764 -2.7%
2011 -564.695 -53.32%
2012 -96.042 -487.97%
2013 -921.187 89.57%
2014 -614.451 -49.92%
2015 -433.340 -41.79%
2016 -1.280.663 66.16%
2017 -537.685 -138.18%
2019 -9.161.395 94.13%
2020 -12.780.000 28.31%
2021 -18.227.000 29.88%
2022 -13.862.000 -31.49%
2023 -2.351.000 -489.62%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Willow Biosciences Inc. Capital Expenditure
Year Capital Expenditure Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1.303.277 100%
2008 711.284 -83.23%
2009 601.300 -18.29%
2010 585.397 -2.72%
2011 149.382 -291.88%
2012 137.900 -8.33%
2013 164.787 16.32%
2014 62.317 -164.43%
2015 217.812 71.39%
2016 239.169 8.93%
2017 -25.942 1021.94%
2019 6.712.423 100.39%
2020 997.000 -573.26%
2021 1.766.000 43.54%
2022 682.000 -158.94%
2023 30.000 -2173.33%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Willow Biosciences Inc. Equity
Year Equity Growth
1998 -143.449
1999 -257.884 44.37%
2000 -441.040 41.53%
2001 -604.347 27.02%
2002 -674.552 10.41%
2003 -980.677 31.22%
2004 -714.971 -37.16%
2005 -109.441 -553.29%
2006 -21.983 -397.84%
2007 2.498.109 100.88%
2008 3.474.699 28.11%
2009 5.240.373 33.69%
2010 3.522.759 -48.76%
2011 2.527.039 -39.4%
2012 901.487 -180.32%
2013 1.436.201 37.23%
2014 1.382.187 -3.91%
2015 1.006.645 -37.31%
2016 -383.335 362.6%
2017 -145.006 -164.36%
2019 22.008.829 100.66%
2020 -559.000 4037.18%
2021 29.682.000 101.88%
2022 16.374.000 -81.28%
2023 5.762.000 -184.17%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Willow Biosciences Inc. Assets
Year Assets Growth
1998 0
1999 0 0%
2000 109.828 100%
2001 99.276 -10.63%
2002 96.401 -2.98%
2003 0 0%
2004 1.060 100%
2005 472.290 99.78%
2006 621.915 24.06%
2007 3.072.411 79.76%
2008 4.373.919 29.76%
2009 5.563.630 21.38%
2010 3.726.065 -49.32%
2011 3.041.747 -22.5%
2012 2.137.102 -42.33%
2013 2.386.065 10.43%
2014 2.428.700 1.76%
2015 2.415.225 -0.56%
2016 1.699.430 -42.12%
2017 724.181 -134.67%
2019 33.883.625 97.86%
2020 21.864.000 -54.97%
2021 35.016.000 37.56%
2022 18.148.000 -92.95%
2023 8.537.000 -112.58%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Willow Biosciences Inc. Liabilities
Year Liabilities Growth
1998 143.449
1999 257.884 44.37%
2000 550.868 53.19%
2001 703.623 21.71%
2002 770.953 8.73%
2003 980.677 21.39%
2004 716.031 -36.96%
2005 581.731 -23.09%
2006 643.898 9.65%
2007 574.302 -12.12%
2008 899.220 36.13%
2009 323.257 -178.17%
2010 203.306 -59%
2011 514.708 60.5%
2012 1.235.615 58.34%
2013 949.864 -30.08%
2014 1.046.513 9.24%
2015 1.408.580 25.7%
2016 2.082.765 32.37%
2017 869.187 -139.62%
2019 11.874.796 92.68%
2020 22.423.000 47.04%
2021 5.334.000 -320.38%
2022 1.774.000 -200.68%
2023 2.775.000 36.07%

Willow Biosciences Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.12
Price to Earning Ratio
-0.82x
Price To Sales Ratio
7.41x
POCF Ratio
-0.89
PFCF Ratio
-0.81
Price to Book Ratio
2.16
EV to Sales
6.14
EV Over EBITDA
-0.97
EV to Operating CashFlow
-0.7
EV to FreeCashFlow
-0.67
Earnings Yield
-1.23
FreeCashFlow Yield
-1.23
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.36
Graham NetNet
0.01

Income Statement Metrics

Net Income per Share
-0.12
Income Quality
0.91
ROE
-1.45
Return On Assets
-1.78
Return On Capital Employed
-2.31
Net Income per EBT
1
EBT Per Ebit
0.98
Ebit per Revenue
-9.83
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
4.22
Research & Developement to Revenue
4.87
Stock Based Compensation to Revenue
0.34
Gross Profit Margin
1
Operating Profit Margin
-9.83
Pretax Profit Margin
-9.6
Net Profit Margin
-9.56

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.11
Free CashFlow per Share
-0.12
Capex to Operating CashFlow
0.04
Capex to Revenue
-0.35
Capex to Depreciation
-0.29
Return on Invested Capital
-1.72
Return on Tangible Assets
-1.78
Days Sales Outstanding
138.16
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
2.64
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,03
Book Value per Share
0,05
Tangible Book Value per Share
0.05
Shareholders Equity per Share
0.05
Interest Debt per Share
0.04
Debt to Equity
0.29
Debt to Assets
0.19
Net Debt to EBITDA
0.2
Current Ratio
3.23
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.29
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
188500
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Willow Biosciences Inc. Dividends
Year Dividends Growth

Willow Biosciences Inc. Profile

About Willow Biosciences Inc.

Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada.

CEO
Dr. Chris Savile
Employee
32
Address
202, 1201-5th Street SW
Calgary, T2R 0Y6

Willow Biosciences Inc. Executives & BODs

Willow Biosciences Inc. Executives & BODs
# Name Age
1 Dr. Trish Choudhary
Senior Vice President of Research & Development
70
2 Dr. Chris Savile
President, Director & Chief Executive Officer
70
3 Mr. Troy T. Talkkari
Vice President of Corporate Development
70
4 Mr. Sanjib Singh Gill L.L.B.
Corporate Secretary
70
5 Mr. Travis Doupe
Chief Financial Officer
70

Willow Biosciences Inc. Competitors